TP63
TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.
Overview
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription.
Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes affected pathway 0.40, literature 0.98, genetic association 0.72, somatic mutation 0.83, animal model 0.75). IntOGen calls it a driver in 5 cohorts (1 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Cervical Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Neuroblastoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.
- 1 · What it is
TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.
- 2 · What goes wrong in cancer
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity.
- 3 · How drugs use it
No product in this corpus aims at TP63 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:15979 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H3D4 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000073282 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.63, melanoma 0.60, non-Hodgkin lymphoma 0.64, skin cancer 0.68, basal cell carcinoma 0.52, breast cancer 0.56 (GraphQL API, CC0)); IntOGen TP63 (driver in 5 cohorts (Act 1, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signalling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. Location: Nucleus (UniProt). Locus 3q28 (HGNC).
- Lung cancer: Open Targets association 0.69 with lung cancer (MONDO_0008903)
- Skin cancer: Open Targets association 0.68 with skin cancer (MONDO_0002898)
- Non-Hodgkin lymphoma: Open Targets association 0.64 with non-Hodgkin lymphoma (MONDO_0018908)
- Leukaemia: Open Targets association 0.60 with leukaemia (MONDO_0005059)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Cervical cancer: IntOGen driver in 1 cohort (CESC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TP63" OR ABSTRACT:"TP63" OR TITLE:"tumor protein p63" OR ABSTRACT:"tumor protein p63" OR TITLE:"Tumor protein 63" OR ABSTRACT:"Tumor protein 63" OR TITLE:"p51" OR ABSTRACT:"p51" OR TITLE:"SHFM4" OR ABSTRACT:"SHFM4" OR TITLE:"EEC3" OR ABSTRACT:"EEC3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TP63, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSND1
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Cervical cancer.
- TargetNSD2
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer.
- TargetDDX3X
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetNOTCH2
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer.
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetRUNX1T1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetCUX1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetNCOR1
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).